SYNCOM FORMULATIONS (INDIA) Financial Statement Analysis
|
||
|
The Revenues of SYNCOM FORMULATIONS (INDIA) have increased by 17.45% YoY .
The Earnings Per Share (EPS) of SYNCOM FORMULATIONS (INDIA) has increased by 96.30 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
SYNCOM FORMULATIONS (INDIA) Last 5 Annual Financial Results
[BOM: 524470|NSE : SYNCOMF]
| Consolidated | Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2017 |
|---|---|---|---|---|---|
| Revenues | ₹263 Cr | ₹224 Cr | ₹220 Cr | ₹18,482,242 Cr | ₹184 Cr |
| Expenses | ₹234 Cr | ₹204 Cr | ₹200 Cr | ₹16,826,961 Cr | ₹167 Cr |
| Operating Profit (Excl OI) | ₹30 Cr | ₹20 Cr | ₹20 Cr | ₹1,655,282 Cr | ₹17 Cr |
| Other Income | ₹14 Cr | ₹15 Cr | ₹12 Cr | ₹279,084 Cr | ₹2.67 Cr |
| Interest | ₹4.47 Cr | ₹3.40 Cr | ₹1.93 Cr | ₹33,442 Cr | ₹0.14 Cr |
| Depreciation | ₹4.72 Cr | ₹4.54 Cr | ₹3.95 Cr | ₹312,282 Cr | ₹3.00 Cr |
| Profit Before Tax | ₹34 Cr | ₹27 Cr | ₹26 Cr | ₹1,587,742 Cr | ₹16 Cr |
| Profit After Tax | ₹25 Cr | ₹20 Cr | ₹20 Cr | ₹1,053,410 Cr | ₹10 Cr |
| Consolidated Net Profit | ₹25 Cr | ₹20 Cr | ₹20 Cr | ₹1,053,410 Cr | ₹10 Cr |
| Earnings Per Share (Rs) | ₹0.53 | ₹0.27 | ₹0.21 | ₹0.23 | ₹0.13 |
| PAT Margin (%) | 10.63 | 9.61 | 8.95 | 9.01 | 5.70 |
| ROE(%) | 15.69 | 9.30 | 8.48 | 11.83 | 9.32 |
| ROCE(%) | 18.77 | 10.98 | 9.68 | 13.72 | 13.28 |
| Total Debt/Equity(x) | 0.01 | 0.25 | 0.32 | 0.27 | 0.11 |
Key Financials |
||
| Market Cap | : | ₹ 1,551.0 Cr |
| Revenue (TTM) | : | ₹ 495.6 Cr |
| Net Profit(TTM) | : | ₹ 57.6 Cr |
| EPS (TTM) | : | ₹ 0.6 |
| P/E (TTM) | : | 26.9 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| SYNCOM FORMULATIONS (INDIA) | -0.6% | 2.3% | -14.6% |
| SUN PHARMACEUTICAL INDUSTRIES | -0.3% | 6% | -10.5% |
| DIVIS LABORATORIES | 3.9% | 18.6% | 14.5% |
| CIPLA | -5.2% | NA | 2.5% |
| TORRENT PHARMACEUTICALS | -1% | -1.2% | 8.7% |
| DR REDDYS LABORATORIES | -6.8% | -2.1% | -8.4% |
| MANKIND PHARMA | -1.4% | -2.2% | 0.7% |
| ZYDUS LIFESCIENCES | -3.9% | -0.7% | -2% |
| LUPIN | 2.2% | 2.8% | -11.8% |
SYNCOM FORMULATIONS (INDIA) Revenues
[BOM: 524470|NSE : SYNCOMF]
| Y-o-Y | 17.45 % |
| 5 Yr CAGR | 9.40 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2025 | ₹263 Cr | 17.45 | |
| Mar2024 | ₹224 Cr | 2.09 | |
| Mar2023 | ₹220 Cr | -100.00 | |
| Mar2022 | ₹18,482,242 Cr | 10,050,222.98 | |
| Mar2017 | ₹184 Cr | - | |
SYNCOM FORMULATIONS (INDIA) Operating Profit
[BOM: 524470|NSE : SYNCOMF]
| Y-o-Y | 48.98 % |
| 5 Yr CAGR | 15.48 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2025 | ₹30 Cr | 48.98 | |
| Mar2024 | ₹20 Cr | -0.67 | |
| Mar2023 | ₹20 Cr | -100.00 | |
| Mar2022 | ₹1,655,282 Cr | 9,930,201.10 | |
| Mar2017 | ₹17 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 26.94 % |
| 5 Yr CAGR | 5.59 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2025 | 11.26% | 26.94 | |
| Mar2024 | 8.87% | -2.74 | |
| Mar2023 | 9.12% | 1.79 | |
| Mar2022 | 8.96% | -1.10 | |
| Mar2017 | 9.06% | - | |
SYNCOM FORMULATIONS (INDIA) Profit After Tax
[BOM: 524470|NSE : SYNCOMF]
| Y-o-Y | 26.12 % |
| 5 Yr CAGR | 25.04 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2025 | ₹25 Cr | 26.12 | |
| Mar2024 | ₹20 Cr | 1.42 | |
| Mar2023 | ₹20 Cr | -100.00 | |
| Mar2022 | ₹1,053,410 Cr | 10,171,878.56 | |
| Mar2017 | ₹10 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | 10.61 % |
| 5 Yr CAGR | 16.86 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2025 | 10.63 % | 10.61 | |
| Mar2024 | 9.61 % | 7.37 | |
| Mar2023 | 8.95 % | -0.67 | |
| Mar2022 | 9.01 % | 58.07 | |
| Mar2017 | 5.7 % | - | |
SYNCOM FORMULATIONS (INDIA) Earnings Per Share (EPS)
[BOM: 524470|NSE : SYNCOMF]
| Y-o-Y | 96.30 % |
| 5 Yr CAGR | 42.10 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2025 | ₹0.53 | 96.30 | |
| Mar2024 | ₹0.27 | 28.57 | |
| Mar2023 | ₹0.21 | -8.70 | |
| Mar2022 | ₹0.23 | 76.92 | |
| Mar2017 | ₹0.13 | - | |
SYNCOM FORMULATIONS (INDIA) Return on Capital Employed (ROCE)
[BOM: 524470|NSE : SYNCOMF]
| Y-o-Y | 70.95 % |
| 5 Yr CAGR | 9.04 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2025 | 18.77% | 70.95 | |
| Mar2024 | 10.98% | 13.43 | |
| Mar2023 | 9.68% | -29.45 | |
| Mar2022 | 13.72% | 3.31 | |
| Mar2017 | 13.28% | - | |
SYNCOM FORMULATIONS (INDIA) Share Price vs Sensex
| Current Share Price | : | ₹16.5 |
| Current MarketCap | : | ₹ 1,551.0 Cr |
| Updated EOD on | : | Oct 31,2025 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| SYNCOM FORMULATIONS (INDIA) | -0.6% |
2.3% |
-14.6% |
| SENSEX | -0.3% |
4.5% |
5.7% |
SYNCOM FORMULATIONS (INDIA) related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE ALLCAP | 6.4% | 8.9% | 7.5% |
| BSE MIDSMALLCAP | 4.7% | 9% | 8.4% |
| BSE SMALLCAP | 0.7% | 3.2% | 2.9% |
| BSE HEALTHCARE | -0.8% | 3.3% | 4% |
No NSE index found
You may also like the below Video Courses
FAQ about SYNCOM FORMULATIONS (INDIA) Financials
How the annual revenues of SYNCOM FORMULATIONS (INDIA) have changed ?
The Revenues of SYNCOM FORMULATIONS (INDIA) have increased by 17.45% YoY .
How the Earnings per Share (EPS) of SYNCOM FORMULATIONS (INDIA) have changed?
The Earnings Per Share (EPS) of SYNCOM FORMULATIONS (INDIA) has increased by 96.30 % YoY .
Check out Intrinsic Value of Peers of SYNCOM FORMULATIONS (INDIA)
Compare Stock Analytics of Peers of SYNCOM FORMULATIONS (INDIA)
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
